Table 1.
Ruxolitinib combinations and single-agents tested in TTP assay
| Treatment/cell line | YT | NK-YS | SNK-6 | NK-92 | NKL | IMC-1 |
|---|---|---|---|---|---|---|
| Mutation in STAT3 or TP53 | STAT3 | STAT3 | STAT3 | TP53 | TP53 | TP53 |
| Dexamethasone + ruxolitinib | Regrowth (day 24) | Non-responding | Responding | Regrowth (day 62) | Responding | Responding |
| Tipifarnib + ruxolitinib | Regrowth (day 44) | Regrowth (day 42) | Responding | Responding | Responding | Responding |
| S63845 + ruxolitinib | Responding | Nonresponding | Regrowth (day 60) | Regrowth (day 41) | Responding | Responding |
| Idasanutlin + ruxolitinib | Responding | Regrowth (day 23) | Responding | Regrowth (day 48) | Regrowth (day 34) | Regrowth (day 18) |
| Ruxolitinib, 100 nM | Nonresponding | Nonresponding | Regrowth (day 56) | Nonresponding | Regrowth (day 34) | Regrowth (day 14) |
| Dexamethasone, 200 nM | Nonresponding | Nonresponding | Nonresponding | Nonresponding | Nonresponding | Nonresponding |
| Tipifarnib, 200 nM | Nonresponding | Regrowth (day 27) | Regrowth (day 35) | Nonresponding | Regrowth (day 17) | Nonresponding |
| S63845, 300 nM | Regrowth (day 30) | Nonresponding | Regrowth (day 24) | Nonresponding | Nonresponding | Nonresponding |
| Idasanutlin, 300 nM | Regrowth (day 24) | Regrowth (day 10) | Responding | Nonresponding | Nonresponding | Nonresponding |
Cells were considered fully responding when no sign of regrowth was visible at the end of the assay. Regrowth day marked in brackets was based on when cells reached 10 million (one doubling). Cells were considered nonresponding when expansion occurred within 9 days of starting treatment.